Linezolid: an oxazolidinone antibiotic for serious Gram‑positive infections

Mechanism and spectrum

Linezolid inhibits bacterial protein synthesis by binding to the ribosomal complex and preventing formation of the initiation complex required for translation. Because of this unique action, it retains activity against some strains that are resistant to other antibiotic classes (treatment‑resistant organisms). Clinically relevant susceptible organisms include streptococci such as streptococci and strains of staphylococci including methicillin‑resistant MRSA; it also has activity against some enterococci.

Common clinical uses

Linezolid is typically used when first‑line drugs cannot be used or when the infecting organism is resistant. Typical indications include complicated skin and soft‑tissue infections such as cellulitis and wound infections (skin infections), and certain forms of pneumonia, including hospital‑acquired or healthcare‑associated cases (pneumonia). It is available in both oral and intravenous formulations, which facilitates switching from IV to oral therapy in appropriate patients.

Safety, monitoring and common adverse effects

For short courses, linezolid is generally well tolerated, but several adverse effects require attention. It can be used in patients with hepatic impairment (liver disease) and in those with reduced renal function (poor kidney function) without routine dose modification in many cases; nevertheless, clinical judgment and monitoring are advised. Reports of harmful effects increase with prolonged therapy.

• Common, usually mild adverse events include headache, diarrhea, and nausea.
• Prolonged therapy has been associated with hematologic changes (for example, thrombocytopenia), peripheral and optic neuropathy, and lactic acidosis in some cases; these risks tend to rise with treatment lasting several weeks and warrant periodic blood counts and clinical review.
• Drug interactions: because linezolid has weak monoamine oxidase inhibitor activity, it can interact with serotonergic or adrenergic drugs and may, rarely, precipitate serotonin syndrome.

History, approval and availability

Linezolid was discovered in the 1990s by researchers at Pharmacia & Upjohn and introduced into clinical use around the turn of the 21st century. It is included on the World Health Organization's List of Essential Medicines, reflecting its role as an important treatment option for resistant Gram‑positive infections. Availability and price vary by country and market; in some settings it has been relatively expensive compared with older agents (pricing and access).

Notable distinctions and practical points

Key distinctions for clinicians are its oral bioavailability (allowing outpatient continuation after IV therapy), its distinct mechanism compared with beta‑lactams and glycopeptides, and the balance between efficacy and safety when used long term. Prescribing decisions should consider pathogen susceptibility, prior therapy, potential drug interactions and the need for monitoring during extended courses.

For detailed prescribing information, local guidelines and infectious disease consultation are advisable when considering linezolid for complex or resistant infections.